{"id":6369,"date":"2022-04-20T06:00:00","date_gmt":"2022-04-20T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/"},"modified":"2022-04-20T06:00:00","modified_gmt":"2022-04-20T06:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-mars-2022","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Positiv utveckling i produktprojekten och i patentportf\u00f6ljen<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under f\u00f6rsta kvartalet 2022<\/strong><\/p>\n<ul>\n<li>Nanexa AB beviljades patent i USA (US 11,214,865 B2) avseende en ALD-reaktor anpassad f\u00f6r storskalig produktion av PharmaShell\u00ae-belagda l\u00e4kemedel.<\/li>\n<li>Nanexa meddelade att bolagets prekliniska utredning indikerar orsaken till och en potentiell l\u00f6sning p\u00e5 de m\u00e5ttliga hudreaktioner som uppkom i den kliniska studien med NEX-18. Med dessa resultat expanderar Nanexa det prekliniska programmet f\u00f6r att optimera formuleringen av NEX-18 och projektet v\u00e4ntas g\u00e5 in i klinik igen under n\u00e4sta \u00e5r.<\/li>\n<li>Nanexa gjorde framsteg i den patentintr\u00e5ngsprocess som bolaget driver mot det amerikanska bolaget Vitrivax, Inc. En amerikansk domstol avslog Vitrivax beg\u00e4ran om att avvisa Nanexas k\u00e4rom\u00e5l avseende patentintr\u00e5ng och Vitrivax yrkande om att skyldigheten att l\u00e4mna ut information (s k discovery) ska upph\u00f6ra. Vidare var Nanexas yrkande om att discovery-processen ska tvingas forts\u00e4tta ocks\u00e5 framg\u00e5ngsrik.<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>Inga v\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 31 mars 2022<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 298 (536) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -12 331 (-6 623) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -12 370 (-6 670) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,24 (-0,29) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -17 934 (22 158) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 87 726 (34 849) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 v\u00e5r hemsida via f\u00f6ljande l\u00e4nk, <a target=\"_blank\" href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"nofollow noopener\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p><strong>Investerarpresentation 20 april kl 10:00<\/strong><\/p>\n<p>En lives\u00e4nd presentation med vd David Westberg och efterf\u00f6ljande fr\u00e5gestund h\u00e5lls kl 10:00 i Infront Direct Studios lokaler och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>Presentationen kan ses p\u00e5 <a href=\"https:\/\/youtu.be\/XFWfYFXK_oU\" target=\"_blank\" rel=\"nofollow noopener\">denna l\u00e4nk<\/a>.  <\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr\/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr\/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar parenterala l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2022-04-20 08:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/eccd5920-de49-43cf-9ad3-99a66cc419a0\/nanexa-delarsrapport-jan-mar-2022.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Nanexa Del\u00e5rsrapport Jan Mar 2022<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Positiv utveckling i produktprojekten och i patentportf\u00f6ljen<\/p>\n","protected":false},"template":"","class_list":["post-6369","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q1_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Positiv utveckling i produktprojekten och i patentportf\u00f6ljen\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-04-20T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022 - Nanexa AB","og_description":"Positiv utveckling i produktprojekten och i patentportf\u00f6ljen","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-04-20T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2022"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}